Claims
- 1. A method to effect haemostasis comprising applying to a surgical joining of two tissues during anastomotic surgery a biomaterial comprised of at least one polysaccharide derivative.
- 2. A method to effect haemostasis comprising applying to a surgical joining of two tissues during anastomotic surgery a biomaterial comprised of at least one polysaccharide derivative and at least one member of the group consisting of natural polymers, semisynthetic polymers, synthetic polymers and pharmacologically active substances.
- 3. The method according to claim 1 or 2 wherein said polysaccharide derivative is a hyaluronic acid derivative, a gellan derivative or an alginate derivative.
- 4. The method according to claim 3, wherein said hyaluronic acid derivative is a hyaluronic acid ester wherein part or all of the carboxylic functions are esterified with an alcohol of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series.
- 5. The method according to claim 3, wherein said hyaluronic acid derivative is an autocrosslinked ester of hyaluronic acid wherein part or all of the carboxy groups are esterified with an alcoholic function of the same or other polysaccharide chain.
- 6. The method according to claim 3, wherein said hyaluronic acid derivative is a crosslinked compound of hyaluronic acid wherein part or all of the carboxy groups are esterified and crosslinked with a polyalcohol of the aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic series.
- 7. The method according to claim 3, wherein said hyaluronic acid derivative is a hyaluronic acid ester derivative wherein a first portion of the carboxy groups is esterified with an araliphatic alcohol and a second portion of the carboxy groups is derivatized with straight aliphatic alcohols of 10-22 carbon atoms.
- 8. The method according to claim 3, wherein said hyaluronic acid derivative is a hemiester of succinic acid or a heavy metal salt of the hemiester of succinic acid with hyaluronic acid or with a partial or total ester of hyaluronic acid.
- 9. The method according to claim 3, wherein said hyaluronic acid derivative is sulphated or N-sulphated.
- 10. The method according to claim 2, wherein said natural polymers are selected from the group consisting of collagen, coprecipitates of collagen and glycosaminoglycans, cellulose and polysaccharides in the form of gels.
- 11. The method according to claim 10, wherein said polysaccharides are selected from the group consisting of chitin, chitosan, pectin or pectic acid, agar, agarose, xanthan, gellan gum, alginic acid, alginates, polymannan or polyglycans, starch and natural gums..
- 12. The method according to claim 2, wherein said semisynthetic polymers are selected from the group consisting of collagen crosslinked with aldehydes or precursors of the same, dicarboxylic acids or their halogenides, diamines, derivatives of cellulose, hyaluronic acid, chitin, chitosan, gellan gum, xanthan, pectin or pectic acid, polyglycans, polymannan, agar, agarose, natural gums and glycosaminoglycans.
- 13. The method according to claim 2, wherein said synthetic polymers are selected from the group consisting of polylactic acid, polyglycolic acid or copolymers of the same or the derivatives thereof, polydioxane, polyphosphazene, polysulphone resins, polyurethane resins and PTFE.
- 14. The method according to claim 2, wherein said pharmacologically active substance is a member selected from the group consisting of anti-inflammatory agents, haemostatic agents, antibiotics, antithombotics, factors able to activate plasminogens and growth factors.
- 15. The method according to claim 2, wherein said pharmacologically active substance is fibrinogen or thrombin.
- 16. The method according to claim 4, wherein said ester derivative of hyaluronic acid is esterified within a range of 60-100%.
- 17. The method according to claim 5, wherein said autocrosslinked derivative of hyaluronic acid is autocrosslinked within a range of 0.5-20%, preferably between 3% and 10%.
- 18. The method according to claim 1 or 2, wherein said biomaterials are in the form of films, gels, sponges, gauzes, nonwoven fabrics, membranes, microspheres, microcapsules, threads, guide channels and associations thereof.
- 19. The method according to claim 1 or 2, wherein said surgery further comprises cardiovascular and peritoneal surgery.
- 20. The method according to claims 1 or 2, wherein said biomaterial surrounds the anastomotic joining.
- 21. The method according to claim 20, wherein said anastomotic joining involves veins and said biomaterial is a gel.
- 22. The method according to claim 20, wherein said anastomotic surgery involves arteries and said biomaterial is a film.
- 23. The method according to claim 3, wherein said biomaterial surrounds the anastomotic surgery.
- 24. The method according to claim 23, wherein said anastomotic joining involves veins and said biomaterial is a gel.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PD97A000170 |
Jul 1997 |
IT |
|
Parent Case Info
[0001] This application is a continuation of U.S. application Ser. No. 09/493,943, filed on Jan. 28, 2000, which is a continuation-in-part of PCT international application No. PCT/EP98/04716, which has an international filing date of Jul. 28, 1998, which designated the United States, the entire contents of which are hereby incorporated by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09493943 |
Jan 2000 |
US |
Child |
10139878 |
May 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/EP98/04716 |
Jun 1998 |
US |
Child |
09493943 |
Jan 2000 |
US |